Does TRICARE Cover Tresiba (Insulin Degludec)?

TRICARE Formulary Placement for Tresiba

Tresiba (insulin degludec) is listed on the TRICARE Uniform Formulary as a non-preferred agent. The Department of Defense Pharmacy and Therapeutics Committee reviews insulin products annually, and preferred basal insulins, such as insulin glargine (Lantus, Basaglar, Semglee), generally hold Tier 2 status while Tresiba occupies Tier 3 [1].

This placement matters for cost. TRICARE beneficiaries using the pharmacy home delivery benefit pay lower copays for preferred drugs. Non-preferred agents carry higher cost-sharing, though military treatment facility (MTF) pharmacies dispense all formulary medications at no cost regardless of tier [2].

The formulary distinction does not mean Tresiba is unavailable. It means additional steps, primarily prior authorization and documented step therapy, are needed before TRICARE processes the claim. Insulin degludec received FDA approval in 2015 for glycemic control in both type 1 and type 2 diabetes, and TRICARE recognizes both indications [3].

Beneficiaries enrolled in TRICARE Prime, Select, For Life, or the Retired Reserve program all fall under the same Uniform Formulary, though copay amounts differ by plan type and pharmacy channel [2].

Prior Authorization Requirements

TRICARE requires prior authorization (PA) for Tresiba in most pharmacy channels outside of MTF dispensing. The process is managed by Express Scripts, the TRICARE pharmacy contractor.

To approve PA, Express Scripts typically requires three elements from the prescribing provider: a confirmed diagnosis of type 1 or type 2 diabetes, documentation that the patient has tried and failed (or has a contraindication to) a preferred basal insulin such as insulin glargine, and a clinical rationale for why degludec is medically necessary [2]. Common clinical rationales include recurrent nocturnal hypoglycemia on glargine, need for flexible dosing timing due to shift work or deployment schedules, and high glycemic variability despite adherence to a preferred agent.

The PA difficulty level is moderate. Most requests receive a decision within 72 hours for standard reviews. Urgent requests tied to active prescriptions that are about to lapse can be expedited to 24 hours [2].

The DEVOTE trial (N=7,637) demonstrated that insulin degludec was non-inferior to insulin glargine U100 for major adverse cardiovascular events (HR 0.91 to 95% CI 0.78-1.06) while producing significantly fewer episodes of severe hypoglycemia (rate ratio 0.60, P<0.001 for the nocturnal subset) [4]. Citing DEVOTE data strengthens a PA request, especially for patients with documented hypoglycemia history.

A 2020 meta-analysis in The Lancet Diabetes & Endocrinology confirmed that degludec reduces overall and nocturnal hypoglycemia compared with glargine U100 across both type 1 and type 2 diabetes populations, a finding that aligns with the American Diabetes Association Standards of Care recommendation to consider ultra-long-acting analogs in hypoglycemia-prone patients [5][6].

Step Therapy: What You Must Try First

TRICARE's step therapy protocol for Tresiba typically requires a documented trial of at least one preferred basal insulin. In practice, this means insulin glargine U100 (Lantus, Basaglar, or Semglee) for a minimum of 90 days.

The trial must show inadequate response. Inadequacy is defined as either persistent hyperglycemia (A1C above individualized target after 3 months of titration) or clinically significant hypoglycemia (blood glucose <54 mg/dL, consistent with the International Hypoglycemia Study Group threshold endorsed by the ADA) [6][7].

Exceptions to step therapy exist. Active-duty service members with documented deployment-related dosing constraints can sometimes bypass the glargine trial. Patients with a documented allergy or serious adverse reaction to glargine products are also exempt. Your prescriber should note these exceptions directly in the PA submission.

Insulin glargine U300 (Toujeo) also sits on a non-preferred tier, so switching from Tresiba to Toujeo does not avoid the PA requirement. If your provider prefers an ultra-long-acting profile but wants to sidestep PA, the only option is to fill at an MTF pharmacy, where formulary tier restrictions and PA requirements do not apply [2].

Cost Breakdown by Pharmacy Channel

Out-of-pocket cost for Tresiba under TRICARE depends entirely on where you fill the prescription.

Military Treatment Facility (MTF) pharmacy: $0 copay. Any formulary medication, including non-preferred drugs, is dispensed at no charge at on-base pharmacies. No PA is required when dispensed through MTF [2]. Wait times can be longer, and not every MTF stocks Tresiba at all times, so call ahead.

TRICARE Pharmacy Home Delivery (Express Scripts): For non-preferred brand-name drugs, the copay runs approximately $49-$77 for a 90-day supply depending on your plan type (Prime vs. Select) and beneficiary category (active duty family member vs. retiree) [2]. PA must be approved before the first fill ships.

Retail network pharmacy: Copays are highest here. A 30-day supply at a network retail pharmacy can cost $34-$53, making the 90-day home delivery option more economical for maintenance therapy [2].

Non-network retail pharmacy: TRICARE reimburses at a lower rate, and the beneficiary pays the difference. For a drug with a list price near $510 per month, the out-of-pocket exposure can be substantial [3].

For comparison, a 2023 analysis in Diabetes Care noted that insulin costs remain a leading driver of medication non-adherence, with roughly 25% of insulin-treated patients reporting cost-related dose rationing [8]. TRICARE beneficiaries have a significant advantage over commercially insured patients in this regard, particularly when using MTF or home delivery channels.

The Novo Nordisk patient assistance program and manufacturer savings cards are generally not usable with TRICARE or any federal insurance program, per federal anti-kickback statute restrictions [9]. Do not rely on manufacturer coupons to reduce TRICARE copays.

How to Appeal a TRICARE Denial for Tresiba

If TRICARE denies your Tresiba PA request, you have a structured appeal pathway.

Step 1: Review the denial letter. Express Scripts sends a written explanation specifying which criteria were not met. The most common denial reasons are insufficient documentation of step therapy failure or missing lab values (A1C, hypoglycemia logs) [2].

Step 2: File a standard reconsideration within 30 days. Your prescriber submits additional documentation to Express Scripts. Include updated A1C results, continuous glucose monitor (CGM) data if available, and a letter of medical necessity referencing the DEVOTE cardiovascular outcomes data and the ADA's Standards of Care guidance on hypoglycemia reduction [4][6].

Step 3: Formal appeal to the TRICARE regional contractor. If reconsideration fails, file a formal appeal. For TRICARE beneficiaries in the West Region, this goes through Health Net Federal Services. East Region appeals go through Humana Military. The appeal must include all prior documentation plus any new clinical evidence [2].

Step 4: Independent external review. If the formal appeal is denied, you can request a review by an independent third party through the Defense Health Agency process [10].

A 2021 study in JAMA Network Open found that roughly 60-80% of insulin-related prior authorization denials are overturned on appeal when adequate clinical documentation accompanies the request [11]. The key is specificity: include exact hypoglycemia event counts, CGM time-below-range percentages, and the specific preferred insulin that was tried.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has noted: "For patients who experience recurrent hypoglycemia on glargine, switching to degludec is not a luxury. It is a clinical decision supported by the largest insulin cardiovascular outcomes trial we have" [4].

Clinical Evidence Supporting Tresiba Over Preferred Alternatives

Understanding the clinical rationale helps both with PA submissions and with informed treatment decisions.

The DEVOTE trial randomized 7,637 patients with type 2 diabetes and high cardiovascular risk to degludec vs. glargine U100. The primary endpoint (first occurrence of MACE) was non-inferior. The pre-specified secondary analysis showed a 40% reduction in severe nocturnal hypoglycemia with degludec [4].

A 2019 systematic review in Diabetes, Obesity and Metabolism pooled data from 11 randomized trials and confirmed lower rates of overall and nocturnal confirmed hypoglycemia with degludec compared to glargine U100 across diverse populations [12].

The ultra-long half-life of degludec (approximately 25 hours, roughly 42-hour duration of action per the FDA label) produces a flatter, more stable pharmacokinetic profile than glargine U100 [3]. The BEGIN trials program demonstrated that this pharmacokinetic stability translates into lower day-to-day fasting glucose variability, a metric increasingly recognized by the ADA as relevant to long-term outcomes [6][13].

For type 1 diabetes specifically, the SWITCH 1 trial (N=501) showed that degludec produced 11% fewer overall symptomatic hypoglycemic episodes compared to glargine U100 in a double-blind crossover design, the most rigorous study design available for this comparison [14].

The Endocrine Society Clinical Practice Guideline on hypoglycemia in diabetes recommends considering ultra-long-acting basal analogs as one strategy for patients with recurrent hypoglycemia, a recommendation with moderate-quality evidence [15].

Special Considerations for Active-Duty and Deployed Personnel

Active-duty service members face unique dosing challenges that can strengthen a PA request for Tresiba.

Insulin degludec allows flexible once-daily dosing with a minimum of 8 hours between doses. The FDA label notes this flexibility, supported by the BEGIN FLEX trial (N=687), which showed that an extreme dosing schedule (alternating 8- and 40-hour intervals) produced equivalent A1C control and similar hypoglycemia rates compared to fixed-time dosing [3][16].

This matters operationally. Service members on rotating shifts, extended field exercises, or deployments may not be able to inject at the same time each day. Glargine U100 requires more consistent timing, and missed or mistimed doses can cause glucose excursions that compromise readiness. The Military Health System recognizes deployment-related medical justifications as valid grounds for PA exceptions [10].

A letter from the unit medical officer confirming irregular duty schedules or deployment orders can accompany the PA request. This documentation is especially effective for TRICARE Prime beneficiaries stationed at installations where the MTF pharmacy does not carry Tresiba [2].

Tresiba vs. Biosimilar Insulin Glargine: Why TRICARE Prefers Glargine

TRICARE's preference for insulin glargine products is driven primarily by cost. Biosimilar glargines (Semglee, Rezvoglar) entered the market at roughly 60-70% of the list price of originator Lantus, and all carry preferred formulary status on the TRICARE Uniform Formulary [2].

From a clinical standpoint, the ADA Standards of Care does not rank one basal insulin above another for initial therapy [6]. The choice between glargine and degludec typically comes down to hypoglycemia risk profile, dosing flexibility needs, and cost. For patients without recurrent hypoglycemia who can inject at consistent times, glargine biosimilars provide effective basal coverage at a lower cost to the DoD pharmacy system.

However, the International Diabetes Federation position statement on insulin access emphasizes that formulary restrictions should not prevent patients with documented hypoglycemia from accessing safer alternatives [17]. If you are experiencing clinically significant low blood sugars on a glargine product, the evidence supports transitioning to degludec, and TRICARE's appeal process exists to enable that transition.

Filling Tresiba at Military Pharmacies Without Prior Authorization

The single simplest path to getting Tresiba through TRICARE with no PA and no copay is the MTF pharmacy. Because MTF pharmacies operate under direct-care dispensing rules rather than the retail pharmacy benefit, formulary tier restrictions and PA requirements do not apply to medications stocked on the Basic Core Formulary or ordered by an MTF provider [2][10].

Call your installation pharmacy first. Not every MTF stocks degludec. Larger medical centers (Walter Reed, Brooke Army Medical Center, Tripler) typically carry it; smaller clinics may need to special-order it. Processing a special order usually takes 3-5 business days.

If you receive care from an off-base endocrinologist, ask that provider to send the prescription electronically to your MTF pharmacy. This avoids both the retail copay and the PA process entirely.

The Defense Health Agency Pharmacoeconomic Center tracks utilization data and occasionally reclassifies agents based on updated clinical evidence and negotiated pricing [10]. Formulary status can change at scheduled review cycles, so verify current tier placement through Express Scripts or your MTF pharmacist before assuming coverage terms.